United States: To List Or Not To List; That Is The Question – The FTC Signals The Potential For Greater Scrutiny Of Patent Information Submissions To FDA - Hyman, Phelps, & McNamara, P.C.

Mondaq

01 Nov 2023 0 shares 1 views

Mondaq

Published 01 Nov 2023

Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny.

United States: A Question 30 Years In The Making: Would A Final LDT Rule Withstand Judicial Scrutiny? - Hyman, Phelps, & McNamara, P.C.

For more than three decades, FDA has claimed that the Federal Food, Drug, and Cosmetic Act (FD&C Act) gives the agency legal..

Mondaq 07 Nov 2023